{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:05:30Z","timestamp":1789560330367,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of elagolix 150 mg once-daily monotherapy in patients with heavy menstrual bleeding associated with uterine leiomyomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>\n                      A phase 4, randomized, double-blind, placebo-controlled, 6-month treatment study was conducted in premenopausal patients aged 18\u201351 years with\n                      <jats:italic toggle=\"yes\">heavy menstrual bleeding<\/jats:italic>\n                      (defined as menstrual blood loss greater than 80 mL during one menstrual cycle) associated with uterine leiomyomas. Patients were randomized 2:1 to receive elagolix 150 mg once daily or placebo. The primary endpoint was reduction in menstrual blood loss volume to less than 80 mL at the final month and at least a 50% reduction in menstrual blood loss volume from baseline to the final month.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 82 randomized patients, 54 received elagolix 150 mg and 28 received placebo. With elagolix, 49.4% (95% CI 35.1\u201363.8%) of patients met the primary endpoint, compared with 23.3% (95% CI 7.2\u201339.5%) of patients who received placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.035). Statistically significant differences between elagolix and placebo in mean reduction of menstrual blood loss from baseline were seen as early as month 1 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.05 for months 1\u20133 and 5). Significantly more patients receiving elagolix experienced suppression of bleeding compared with placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.036). Greater improvements were observed in the elagolix group (vs placebo) in the proportion of patients with amenorrhea, in hemoglobin concentrations, and in health-related quality of life. No serious or severe adverse events were reported for elagolix, compared with 7.1% of participants in the placebo group having serious adverse events (coronavirus disease 2019 [COVID-19] n=1, enlarged uvula n=1). Three patients (5.6%) discontinued elagolix due to adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Elagolix 150 mg once-daily monotherapy significantly improved heavy menstrual bleeding associated with uterine leiomyomas compared with placebo in premenopausal patients. Treatment with elagolix 150 mg once daily was generally well-tolerated in this study, with no new safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING SOURCE:<\/jats:title>\n                    <jats:p>AbbVie Inc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT03886220.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005380","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:34:13Z","timestamp":1695922453000},"page":"1068-1076","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas"],"prefix":"10.1097","volume":"142","author":[{"given":"Eric","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juki","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Pinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose W.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Snabes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"591.e1","DOI":"10.1016\/j.ajog.2018.09.039","article-title":"A US population-based study of uterine fibroid diagnosis incidence, trends, and prevalence: 2005 through 2014","volume":"219","author":"Yu","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R3-20260916","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"211.e1","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/whe.15.87","article-title":"Hysterectomy for heavy menstrual bleeding","volume":"12","author":"van der Meij","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/oxfordjournals.humrep.a138762","article-title":"Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years","volume":"9","author":"Friedman","year":"1994","journal-title":"Hum Reprod"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/archinte.164.18.1965","article-title":"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review","volume":"164","author":"Gomes","year":"2004","journal-title":"Arch Intern Med"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/13697137.2012.656254","article-title":"Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials","volume":"15","author":"Henderson","year":"2012","journal-title":"Climacteric"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2014is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"R10-20260916","first-page":"290","article-title":"The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata","volume":"99","author":"Spies","year":"2002","journal-title":"Obstet Gynecol"},{"key":"R11-20260916","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jval.2012.03.1387","article-title":"Validation of the UFS-QOL-hysterectomy questionnaire: modifying an existing measure for comparative effectiveness research","volume":"15","author":"Coyne","year":"2012","journal-title":"Value Health"},{"key":"R13-20260916","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/psp4.12560","article-title":"Exposure-safety analyses identify predictors of change in bone mineral density and support elagolix labeling for endometriosis-associated pain","volume":"9","author":"Abbas Suleiman","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:05:37Z","timestamp":1789556737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005380"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005380","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"2022-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}